Company Overview
Omeros Corporation operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics, with a specific focus on orphan indications that target immunologic diseases. The company functions within the healthcare sector and the biotechnology industry, positioning itself to address rare and specialized medical conditions through innovative drug candidates. Currently, the organization employs 202 individuals and holds a total market capitalization of $765.02M, reflecting the market's valuation of its future potential despite the absence of reported annual revenue in the provided data. This market cap figure indicates that the company is valued based on its pipeline assets and strategic positioning rather than current profitability, which is typical for clinical-stage entities that have not yet generated significant commercial sales. The scale of the enterprise, characterized by a workforce of 202 employees and a market valuation of approximately three-quarters of a billion dollars, suggests a mid-cap profile focused on high-risk, high-reward therapeutic advancements in the immunologic disease space.
Financial Health
The company reports a net income of $-121,239,000 and an EBITDA of $-128,345,000 over the trailing twelve-month period, while the revenue figure is listed as N/A in the available data. The substantial gap between the reported net income and the EBITDA figure reveals a cost structure heavily influenced by non-operating expenses or specific accounting adjustments, as the difference between the two measures amounts to approximately $7 million. Free cash flow stands at $-71,538,128, indicating that the company is currently burning cash to fund its research and development activities rather than generating liquidity from operations. This negative free cash flow position implies limited financial flexibility for capital expenditures or acquisitions without securing additional financing or capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved positive profitability on a percentage basis, a common characteristic of early-stage biotechnology firms before product commercialization. On the balance sheet, the company holds $36.09M in cash against $363.44M in debt, resulting in a negative price-to-book ratio of -3.43 and a debt-to-equity ratio that is not available due to negative equity. The current ratio is 0.89, which suggests that the company's current assets are insufficient to cover its current liabilities without relying on asset sales or external funding. Return on Equity is N/A, while Return on Assets is -32.4%, metrics that collectively reveal that management is currently generating negative returns on the capital deployed in the business.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive net income, whereas the forward P/E ratio is 22.17, implying that the market is pricing in expected future earnings growth once the company transitions from a loss-making to a profitable state. The price-to-book ratio is -3.43, a negative figure that indicates the market is valuing the company at a discount relative to its book value, often seen in distressed or highly speculative biotechnology stocks. The price-to-sales ratio is N/A and the EV/EBITDA is -8.63, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable in their standard positive forms for this specific reporting period. The 52-week high is $17.65 and the 52-week low is $2.95, meaning the stock has experienced significant volatility within a range of over $14 per share during the year. The beta value is 2.52, which indicates that the stock's price volatility is more than twice as high as the broader market, reflecting the heightened risk associated with clinical-stage biotechnology investments. These valuation metrics combined suggest a high-risk profile where the market is attempting to value a company with limited current financial performance but significant potential upside if clinical trials succeed.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A in the available facts, preventing a direct comparison of growth rates between revenue and earnings at this specific point in time. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders at this stage of its development. Because the company is not a dividend payer, it retains all available earnings, if any, to reinvest into research and development, clinical trials, and operational expansion rather than paying out cash to investors. The overall growth and income profile is characterized by a reliance on future commercial success rather than current earnings growth or dividend income, typical for clinical-stage biopharmaceutical companies that prioritize pipeline advancement over immediate shareholder returns.